证券代码：002173 证券简称：创新医疗 公告编号：2026-001 创新医疗管理股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 创新医疗管理股份有限公司（以下简称"公司"）股票（证券简称：创新医 疗，股票代码：002173）于2026年1月5日、6日、7日连续三个交易日内日收盘价 格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》的有关规定，公 司股票属于交易异常波动的情形。 二、公司关注、核实情况的说明 针对公司股票交易异常波动情况，公司对控股股东及实际控制人、公司董事 及高级管理人员就相关问题进行了核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 1、公司经过自查不存在违反信息公平披露的情形。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、近期公司生产经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东及实际控制人不存在应披露而未披露的重大事项，也不 存在未披露的处于筹划阶段的重大事项。 ...

2026年A股开门红，脑机接口相关概念股均迎来暴涨。 自1月5日开始，三博脑科（301293）、翔宇医疗、美好医疗（301363）、伟思医疗、诚益通（300430） 等股票连续多个交易日出现20%涨停，冠昊生物（300238）、塞力医疗（603716）、创新医疗 （002173）、南京熊猫（600775）、岩山科技（002195）等也都连续10%涨停。截至1月7日记者发稿， 脑机接口板块依然涨停不断。 多重利好消息传来 消息面上，埃隆.马斯克近日表示，旗下脑机接口公司Neuralink将于2026年开始大规模生产脑机接口设 备，并将同步推进流程高度精简、几乎完全自动化的外科手术方案。这一表态更是引发脑机接口相关概 念股热度快速攀升。有消息称，量产后，脑机单台植入手术的成本将从百万美元降至10万美元以内，全 自动化落地后有望进一步下探至5万美元区间，为日后脑机接口设备的大规模商业化埋下伏笔。 国内政策层面，2025年7月，工业和信息化部、国家发展改革委、教育部、国家卫生健康委、国务院国 资委、中国科学院、国家药监局七部门联合印发《关于推动脑机接口产业创新发展的实施意见》（以下 简称《意见》），首次系统性地明确了 ...

Group 1 - The brain-computer interface sector opened high again, indicating strong investor interest and market momentum [1] - Companies such as Beiyikang and Meihao Medical reached new highs, reflecting positive performance and growth potential [1] - Innovative Medical, Nanjing Panda, and Yanshan Technology achieved three consecutive trading limit ups, showcasing significant market enthusiasm [1] Group 2 - Sanbo Brain Science and Daoshi Technology also experienced upward movement, indicating a broader trend of growth within the sector [1]

Core Viewpoint - The brain-computer interface (BCI) concept continues to gain traction, with multiple listed companies responding positively to the trend, leading to significant stock price increases in the sector [1]. Company Responses - On January 6, several companies, including Weisi Medical, Sanbo Brain Science, Aipeng Medical, and others, saw their stocks hit the daily limit, with many achieving consecutive gains [3]. - Weisi Medical reported a 20.01% increase in stock price, indicating a strong market response to its developments in the neuro-rehabilitation field, expanding from single-device solutions to comprehensive "diagnosis-treatment-rehabilitation" offerings [4][5]. - Sanbo Brain Science highlighted the promising applications of BCI technology in clinical diagnosis and neuro-rehabilitation, also achieving a 20.01% stock price increase [7]. - Xiangyu Medical announced the establishment of a BCI laboratory and aims to develop a product system covering four major categories, also achieving a two-day stock increase [8]. - Aipeng Medical's stock rose by 20%, emphasizing the role of BCI as a bridge between the brain and external devices [9][10]. - Entropy Technology and Meihua Medical also reported significant stock increases, with the former focusing on BCI and vehicle-road collaboration technologies [11][12]. Industry Developments - Companies are actively engaging in the BCI sector, with Xiangyu Medical entering over 500 medical institutions and aiming for over a thousand top-tier hospitals nationwide, indicating a robust commercialization strategy [15]. - Mcland anticipates obtaining its first BCI medical device registration certificate by Q1 2026, which could accelerate the application of BCI technology in existing product lines [15]. - Chengdu Huayi and Yingjixin are focusing on the foundational hardware for BCI, with Chengdu Huayi developing high-precision ADCs and low-power FPGAs for signal processing [15][16]. - The integration of BCI with embodied intelligence is gaining attention, with companies exploring applications in smart healthcare and rehabilitation [17]. - Blue Si Technology announced its strategic investment in Qiang Brain Technology, which recently secured approximately 2 billion yuan in funding, marking it as the second-largest financing in the BCI field after Neuralink [18]. Market Outlook - The global BCI market is projected to reach approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, driven by technological advancements and increased capital investment [20]. - The transition of BCI from clinical validation to commercial scalability is expected to unlock significant market opportunities in healthcare and consumer sectors [20].

Group 1 - The brain-computer interface (BCI) concept stocks have experienced a surge, with 20 stocks hitting the daily limit up for two consecutive days, indicating strong market interest in companies involved in this sector [2][19][21] - The Shanghai Composite Index has reached a ten-year high, marking the 13th consecutive trading day of gains, suggesting a new upward trend in the A-share market [20][21] - Notable BCI stocks that have hit the daily limit include Innovation Medical, Rock Mountain Technology, Sanbo Brain Science, and others, reflecting the growing popularity of this sector [20][21] Group 2 - The Sai Ling International Investment Fund (Shanghai) has invested in several leading companies in the BCI field, including Shanghai Brain Tiger Technology, Beijing Pinchi Medical, and Beijing Brain Land Technology, indicating a strong focus on top-tier technology in this industry [22][31] - Shanghai Brain Tiger Technology is recognized as a leader in the invasive BCI sector, having developed a unique high-throughput flexible BCI technology and achieved significant clinical milestones [24][28] - Beijing Pinchi Medical specializes in invasive BCI technology and has developed a rechargeable directional Bluetooth perceivable brain pacemaker, which has been recognized as one of the top innovations in the BCI field [29][12] Group 3 - Beijing Brain Land Technology is the first company to focus on consumer-grade BCIs, with a strong emphasis on non-invasive BCI research and development, and has received multiple patents for its products [14][32] - Huake Precision (Beijing) Medical Equipment Co., Ltd. is a high-tech enterprise in the neurosurgery field, focusing on the development of medical electrodes and BCI technology, with several medical device registrations [33][16] - Beijing Mind Ark Technology Development Co., Ltd. has developed a near-infrared brain function imaging system, showcasing significant technological advantages in various applications, including mental health and brain-machine interfaces [34][17]

Group 1 - The core viewpoint of the article emphasizes the importance of timely and relevant research reports in identifying investment opportunities, particularly in emerging fields like brain-computer interfaces [1] - Neuralink, led by Elon Musk, is set to begin large-scale production of brain-computer interface devices in 2026, marking a significant milestone in the integration of life sciences and information technology [1] - The brain-computer interface sector is experiencing rapid technological advancements and policy support, with expectations for commercialization to expand into AI applications and robotics by 2026 [1] Group 2 - The article highlights five key focus areas for investment as the humanoid robot sector approaches critical production milestones, with supply chains becoming more consolidated [2] - The AI wave is driving significant increases in storage prices, with DRAM prices soaring by 171.8%, while domestic wafer manufacturers are accelerating "domestic substitution" in response to tightening overseas restrictions [2] - New policies in Guangdong are encouraging insurance capital to enter the market, providing a dual boost to insurance stocks through asset and liability management [2] - A major state-owned enterprise has invested 1 billion in Thunderbird Innovation, signaling an imminent explosion in the AI glasses sector [2]

（原标题：揭秘涨停丨脑机接口热门股封单超22亿元） 截至收盘，上证指数报收4083.67点，上涨1.50%；深证成指收于14022.55点，上涨1.40%。创业板指上 涨0.75%；科创50指数上涨1.84%。 不含未开板新股，今日（1月6日）可交易A股中，上涨个股超4100只，占比超75%，下跌个股有1222 只。其中，收盘封死涨停的有144只，30股封板未遂，整体封板率为82.76%。 据证券时报•数据宝统计，封死涨停个股中，以所属行业来看，涨停个股居前的行业有基础化工、机械 设备、国防军工，分别有18只、17只、15只。 封死涨停股中，*ST阳光、ST中迪等23只股为ST股。从连续涨停天数来看，胜通能源已连收13个涨停 板，连续涨停板数量最多。 以封单金额计算，岩山科技、锋龙股份、创新医疗等涨停板封单资金最多，分别有22.12亿元、13.87亿 元、13.52亿元，其中岩山科技、创新医疗均为脑机接口热门股。从封单力度（封单量占流通A股比例） 来看，农心科技、锋龙股份、创新医疗等力度较大，分别为27.43%、17.97%、12.47%。 声明：数据宝所有资讯内容不构成投资建议，股市有风险，投资需谨慎。 校 ...

截至收盘，上证指数报收4083.67点，上涨1.50%；深证成指收于14022.55点，上涨1.40%。创业板指上 涨0.75%；科创50指数上涨1.84%。 不含未开板新股，今日（1月6日）可交易A股中，上涨个股超4100只，占比超75%，下跌个股有1222 只。其中，收盘封死涨停的有144只，30股封板未遂，整体封板率为82.76%。 | 代码 | 名称 | 涨停封单额 | 涨停板 | 涨停原因 | | --- | --- | --- | --- | --- | | | | (亿元) | 情況 | | | 002195 岩山科技 | | 22.12 | 2连板 | 脑机接口+具身智能+AI应用 | | 002931 | 锋龙股份 | 13.87 | 8连板 | 优必选拟入主+机器人+复牌 | | 002173 | 创新医疗 | 13.52 | 2连板 | 脑机接口+民营医院+高压氧舱 | | 600775 | 南京龍猫 | 7.98 | 2连板 | 脑机接口+卫星通信+智能制造+央企 | | 301293 | 一博脑科 | 7.25 | 2连板 | 脑机接口+神经专科+基金布局 | | 301363 | ...

今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002195 | 岩山科 技 | 10.00 | 1.28 | 49272.01 | 80.37 | | 300430 | 诚益通 | 19.99 | 34.79 | 18886.96 | 7.85 | | 301293 | 三博脑 科 | 20.01 | 2.21 | 14128.55 | 46.71 | | 002173 | 创新医 疗 | 10.02 | 1.26 | 11284.03 | 82.52 | | 000516 | 国际医 学 | 9.96 | 2.16 | 9211.37 | 37.34 | | 603716 | 塞力医 疗 | 10.00 | 3.53 | 7079.50 | 38.34 | | 300753 | 爱朋医 | 20.00 | 17.90 | 7057.72 | 11.41 | | --- | --- | --- ...

Group 1 - The high-pressure oxygen chamber concept has seen a significant increase of 6.13%, making it the top-performing sector today, with 10 stocks rising, including BeiYikang which hit a 30% limit up, and others like Innovation Medical and International Medicine also reaching their daily limit [1][2] - Major stocks in the high-pressure oxygen chamber sector include Samsung Medical, Weiao Co., and Hangyang Co., which increased by 5.88%, 3.92%, and 3.20% respectively [1][2] Group 2 - The high-pressure oxygen chamber sector attracted a net inflow of 216 million yuan from main funds today, with Innovation Medical leading the inflow at 113 million yuan, followed by International Medicine, Samsung Medical, and Hangyang Co. [2] - The net inflow ratios for key stocks in the sector are as follows: Innovation Medical at 82.52%, International Medicine at 37.34%, and Weiao Co. at 4.50% [3]